Linezolid for Syphilis Pilot Study
Launched by UNIVERSITY OF SOUTHERN CALIFORNIA · Sep 16, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Linezolid for Syphilis Pilot Study is a research trial aimed at exploring whether the antibiotic linezolid can effectively treat syphilis, a sexually transmitted infection. The study is currently recruiting participants who are 16 years of age or older and have been diagnosed with primary, secondary, or early latent syphilis. To be eligible, participants must also have a specific blood test result indicating the presence of the infection and, if they are living with HIV, must be on treatment with a controlled viral load.
Participants in this trial can expect to receive linezolid as part of their treatment. They will be closely monitored throughout the study, and their health will be evaluated to determine how well the medication works against syphilis. However, certain individuals cannot participate, including those who are pregnant, have specific mental health medication prescriptions, or have recent treatment with certain antibiotics. This study is an important step in finding new treatment options for syphilis and could contribute to better care for those affected by this infection.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 16 years of age or older
- • Diagnosed cases of primary, secondary, or early latent syphilis with RPR titer ≥1:8 within 3 weeks prior to enrollment
- • Able to provide informed consent
- • For PLHIV: on treatment for HIV-infection and most recent viral load \<200 copies/mL or most recent CD4 T-cell count \>350 cells/mL
- Exclusion Criteria:
- • Pregnancy or a positive pregnancy test on the day of enrollment
- • Participants who receive certain psychotropic medications, e.g., MAO inhibitors, SNRIs, SSRIs
- • Patients showing signs and symptoms of neurosyphilis
- • Serofast RPR titer
- • Recent (\<7 days) or concomitant antimicrobial therapy with azithromycin, doxycycline, ceftriaxone, cefixime, or other beta lactam antibiotics (e.g. amoxicillin)
- • Linezolid or penicillin allergy
About University Of Southern California
The University of Southern California (USC) is a prestigious research institution located in Los Angeles, California, known for its commitment to advancing knowledge and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, USC leverages its extensive resources, interdisciplinary expertise, and state-of-the-art facilities to conduct cutting-edge research aimed at improving patient outcomes and public health. The university fosters collaboration among its diverse faculty and students, ensuring a dynamic environment for the development and implementation of clinical studies that adhere to the highest ethical and scientific standards. Through its clinical trials, USC aims to contribute to the advancement of medical science and the translation of research findings into practical applications that benefit communities locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jackson, Mississippi, United States
Chicago, Illinois, United States
Patients applied
Trial Officials
Jeffrey D Klausner, MD MPH
Principal Investigator
University of Southern California
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials